XML 39 R27.htm IDEA: XBRL DOCUMENT
v3.21.1

Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately-held Companies (Details Textual) € in Millions |  |  | 3 Months Ended |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Jun. 24, 2020 | Jun. 30, 2017 EUR (€) | Mar. 31, 2021 USD ($) | Mar. 31, 2020 USD ($) | Dec. 31, 2020 USD ($) | Dec. 01, 2020 | Jul. 08, 2020 shares | Apr. 26, 2019 | Jun. 30, 2017 USD ($) | Jun. 30, 2017 EUR (€)
Collaborative Arrangement, Duration Of Agreement (Year) |  | 2 years |  |  |  |  |  |  |  |
Collaborative Arrangement, Payment for Research and Development Agreement | € |  | € 1.1 |  |  |  |  |  |  |  |
Cost of Goods and Services Sold, Total |  |  | $ 390,762 | $ 278,182 |  |  |  |  |  |
Novovet [Member] |  |  |  |  |  |  |  |  |  |
Equity Method Investment, Ownership Percentage |  |  |  |  |  |  |  | 20.00% |  |
Alphazyme [Member] |  |  |  |  |  |  |  |  |  |
Sale of Stock, Percentage of Ownership after Transaction | 2.50% |  |  |  |  |  |  |  |  |
Equity Securities without Readily Determinable Fair Value, Amount |  |  |  |  | $ 284,709 |  |  |  |  |
Service Agreement to Perform Research Project [Member] | BDI [Member] |  |  |  |  |  |  |  |  |  |
Cost of Goods and Services Sold, Total |  |  | $ 15,000 |  |  |  |  |  |  |
Research Services Agreement [Member] |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Payment for Additional Development and Commercialization | € |  |  |  |  |  |  |  |  |  | € 1.5
Service Framework Agreement [Member] |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Duration Of Agreement (Year) |  | 2 years |  |  |  |  |  |  |  |
Collaborative Arrangement, Minimum Obligation For Research and Development |  |  |  |  |  |  |  |  | $ 1,000,000.0 |
Collaborative Arrangement, Outstanding Commitment |  |  |  |  |  |  |  |  | 1,000,000.0 |
Alphazyme [Member] |  |  |  |  |  |  |  |  |  |
Ownership Percentage |  |  |  |  |  | 1.99% |  |  |  |
ID Biologics Inc [Member] |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Number of Shares To Be Received (in shares) | shares |  |  |  |  |  |  | 129,611 |  |  |
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners |  |  |  |  |  |  | 0.37% |  |  |
ID Biologics Inc [Member] | Share-based Payment Arrangement, Tranche One [Member] |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Vesting Percentages |  |  |  |  |  |  | 50.00% |  |  |
ID Biologics Inc [Member] | Share-based Payment Arrangement, Tranche Two [Member] |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Vesting Percentages |  |  |  |  |  |  | 25.00% |  |  |
ID Biologics Inc [Member] | Share-based Payment Arrangement, Tranche Three [Member] |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Vesting Percentages |  |  |  |  |  |  | 25.00% |  |  |
Research Services Agreement [Member] |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Payment for Research and Development Agreement | € |  | € 1.0 |  |  |  |  |  |  |  |
Research Services Agreement [Member] | BDI Holdings [Member] |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Duration Of Agreement (Year) |  | 2 years |  |  |  |  |  |  |  |
Collaborative Arrangement, Equity Interest Acquired |  | 16.10% |  |  |  |  |  |  |  |
Collaborative Arrangement, Minimum Obligation For Research and Development |  |  |  |  |  |  |  |  | $ 936,000 |
Collaborative Arrangement, Maximum Obligation For Research and Development | € |  |  |  |  |  |  |  |  |  | 8.0
Research Services Agreement [Member] | BDI Holdings [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Minimum Obligation For Research and Development | € |  |  |  |  |  |  |  |  |  | € 1.0
Collaborative Arrangement, Revenue Sharing, Percentage |  | 50.00% |  |  |  |  |  |  |  |
Research Services Agreement [Member] | BDI Holdings [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Revenue Sharing, Percentage |  | 75.00% |  |  |  |  |  |  |  |
Research Services Agreement [Member] | VL Pbio Member |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Equity Interest Acquired |  | 3.30% |  |  |  |  |  |  |  |

X
- Definition Represents duration of agreement for collaborative agreement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementDurationOfAgreement
Namespace Prefix: | dyai_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents equity interest acquired for collaborative agreement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementEquityInterestAcquired
Namespace Prefix: | dyai_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents maximum obligation for research and development for collaborative agreement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents minimum obligation for research and development for collaborative agreement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents number of shares to be received for collaborative arrangement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementNumberOfSharesToBeReceived
Namespace Prefix: | dyai_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents outstanding commitment for collaborative. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementOutstandingCommitment
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents payments for additional development and commercialization for collaborative arrangement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementPaymentForAdditionalDevelopmentAndCommercialization
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents payment for research and development agreement for collaborate arrangement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents percentage of revenue sharing for collaborate arrangement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementRevenueSharingPercentage
Namespace Prefix: | dyai_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents vesting percentage for collaborative arrangement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementVestingPercentages
Namespace Prefix: | dyai_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents ownership percentage by noncontrolling owners for noncontrolling interest. + References No definition available. + Details
Name: | dyai_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners
Namespace Prefix: | dyai_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of ownership. + References No definition available. + Details
Name: | dyai_OwnershipPercentage
Namespace Prefix: | dyai_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a),(d)) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 + Details
Name: | us-gaap_CostOfGoodsAndServicesSold
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of investment in equity security without readily determinable fair value. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 321 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120269885&loc=SL75117539-209714 + Details
Name: | us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dyai_NovovetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dyai_AlphazymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=dyai_ServiceAgreementToPerformResearchProjectMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=dyai_BDIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedContractCostAxis=dyai_ResearchServicesAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedContractCostAxis=dyai_ServiceFrameworkAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=dyai_AlphazymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=dyai_IDBiologicsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dyai_ResearchServicesAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=dyai_BDIHoldingsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=dyai_VLPbioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |